Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Genmab A/S Sponsored ADR GMAB

Healthcare  —  Biotechnology
35.32 0.49 1.41% as of 25 Sep
Market cap
$20.8B
P/E
27.8×
Cash Flow Champion (3y) Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Genmab A/S Sponsored ADR (GMAB) Business Profile

Updated before January 2025

Company Overview

Genmab A/S Sponsored ADR (GMAB) is a leading international biotechnology company specializing in the development of innovative antibody therapeutics for the treatment of cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has established itself as a pioneer in the biotechnology sector. The company was co-founded by Lisa N. Drakeman, Ph.D., and Jan G. J. van de Winkel, Ph.D., who currently serves as the President and Chief Executive Officer (CEO). Genmab is listed on the Nasdaq Copenhagen and trades as an American Depositary Receipt (ADR) on the Nasdaq Global Select Market under the ticker symbol GMAB.

Genmab’s leadership team is composed of experienced professionals with deep expertise in biotechnology, pharmaceuticals, and business development. Under the guidance of Dr. van de Winkel, the company has achieved significant milestones in the development of antibody-based therapies, making it a key player in the global biopharmaceutical industry.

Core Business Segments

Genmab focuses on the research, development, and commercialization of antibody-based therapies. Its core business segments include:

1. Oncology Therapeutics

Genmab’s primary focus is on developing innovative treatments for cancer. The company’s portfolio includes several groundbreaking products:

  • DARZALEX® (daratumumab): A monoclonal antibody used for the treatment of multiple myeloma. DARZALEX® has become a cornerstone therapy in the treatment of this disease.
  • TEPEZZA® (teprotumumab): Although primarily developed for thyroid eye disease, this product showcases Genmab’s expertise in antibody technology.
  • KESIMPTA® (ofatumumab): A treatment for relapsing forms of multiple sclerosis, highlighting the company’s expansion into autoimmune diseases.

2. Proprietary Antibody Technologies

Genmab has developed proprietary antibody technologies that form the backbone of its product pipeline:

  • DuoBody® Technology: A platform for creating bispecific antibodies that can target two different antigens simultaneously.
  • HexaBody® Technology: A platform designed to enhance the potency of antibodies by inducing hexamer formation.
  • HexElect® Technology: A novel approach combining HexaBody® and DuoBody® technologies to create highly potent and selective antibodies.

3. Collaborative Partnerships

Genmab collaborates with leading pharmaceutical companies to co-develop and commercialize its therapies. Key partnerships include collaborations with Janssen Biotech, Novartis, and Seagen, which have significantly contributed to the company’s revenue and global reach.

Business Model

Genmab operates a hybrid business model that combines proprietary product development with strategic partnerships. The company generates revenue through:

  1. Product Sales: Royalties from the sales of marketed products like DARZALEX® and TEPEZZA®.
  2. Collaborative Agreements: Upfront payments, milestone payments, and royalties from partnerships with pharmaceutical companies.
  3. Licensing of Technologies: Revenue from licensing its proprietary antibody platforms to other biotech and pharmaceutical companies.

This diversified revenue stream allows Genmab to reinvest in research and development (R&D), ensuring a robust pipeline of innovative therapies.

Strategic Direction

Genmab’s strategic vision is centered on becoming a fully integrated biotechnology company. Key elements of its strategic direction include:

  1. Pipeline Expansion: Genmab aims to advance its pipeline of antibody-based therapies, focusing on oncology and autoimmune diseases.
  2. Sustainability Goals: The company is committed to reducing its environmental footprint and integrating sustainability into its operations.
  3. Global Reach: Genmab plans to expand its presence in key markets, including North America, Europe, and Asia.
  4. Innovation: Continued investment in R&D to develop next-generation antibody technologies and therapies.

Competitive Landscape

Genmab operates in a highly competitive biotechnology sector. Key competitors include:

  • Roche: A global leader in oncology and antibody-based therapies.
  • Amgen: Known for its innovative biologics and biosimilars.
  • Regeneron Pharmaceuticals: A major player in antibody therapeutics.
  • AstraZeneca: Focused on oncology and immunology.

Despite the competition, Genmab’s proprietary technologies and strategic partnerships provide a competitive edge.

Risk Factors

Genmab faces several risks that could impact its business:

  1. Market Dependence: Heavy reliance on the success of key products like DARZALEX®.
  2. Regulatory Challenges: Stringent regulatory requirements for drug approval.
  3. Supply Chain Disruptions: Potential delays in manufacturing and distribution.
  4. Competition: Intense competition from established biotech and pharmaceutical companies.
  5. R&D Uncertainty: High costs and risks associated with drug development.

Recent Developments

Genmab has made significant progress in recent years:

  • New Product Approvals: Expansion of indications for DARZALEX® and other therapies.
  • Collaborations: Strengthened partnerships with Janssen and Novartis to co-develop new therapies.
  • Technological Advancements: Continued innovation in DuoBody® and HexaBody® platforms.
  • Global Expansion: Increased presence in the U.S. and Asian markets.

Investment Considerations

Strengths:

  • Strong pipeline of innovative therapies.
  • Proven track record of successful product launches.
  • Robust revenue growth driven by royalties and partnerships.
  • Proprietary antibody technologies with broad applications.

Risks:

  • Dependence on a few key products for revenue.
  • High R&D costs and long development timelines.
  • Exposure to regulatory and competitive pressures.

Conclusion

Genmab A/S Sponsored ADR (GMAB) is a leading biotechnology company with a strong focus on antibody-based therapies. Its innovative technologies, strategic partnerships, and robust pipeline position it as a key player in the biopharmaceutical industry. While the company faces risks such as market dependence and regulatory challenges, its commitment to innovation and global expansion provides a solid foundation for future growth. Investors seeking exposure to the biotechnology sector may find Genmab an attractive option, given its proven track record and growth potential.